Precision Oncology India is increasingly defined by a practical shift: matching therapy to a patient’s tumor biology using biomarkers. Industry research frames precision oncology as diagnostics and therapies guided by biomarkers, using tumor genetics, protein expression, and other molecular traits to connect patients with tailored options. This approach is also reflected in how more cancers are being classified by actionable mutations, receptor expression, and immune biomarkers, which supports biomarker-guided immunotherapy and targeted treatment selection. As companion diagnostics and molecular profiling become more embedded in treatment protocols, the need for reliable biomarker testing rises alongside it.
India’s cancer biomarkers market projections illustrate how quickly the testing side of this model is scaling. MarketsandMarkets estimates the India Cancer Biomarkers Market at $558.8 million in 2026, projected to reach $1297.5 million by 2031, representing a 15.1% CAGR. The same source links this trajectory to growing adoption of precision medicine and personalized cancer treatment approaches, along with demand for early detection and diagnostic biomarkers. It also notes that this accelerated growth in India outpaces the global average of 11.6%, and attributes momentum to improved healthcare accessibility, rising awareness of precision oncology, and improving diagnostic infrastructure.
From Testing to Treatment: Biomarkers Start Driving Decisions
Biomarker-guided treatment depends on both what is measured and how results translate into therapy choices. Mordor Intelligence reports that genomic biomarkers accounted for 31.48% of the precision oncology market size in 2025, while next-generation sequencing represented 36.73% by technology in 2025. The same report adds that fluorescence in situ hybridization (FISH) is expected to advance at a 10.72% CAGR through 2031, and that epigenomic biomarkers are projected to grow at an 8.79% CAGR through 2031. In practice, these trends align with the broader push toward companion diagnostics, molecular profiling, and biomarker testing as crucial tools for identifying suitable patients and improving response.
On the therapy side, market projections suggest expanding demand for targeted, stratified care models in India. Mobility Foresights projects the India Precision Therapeutics Market will grow from USD 142.5 billion in 2025 to USD 356.8 billion by 2032, registering a 14.0% CAGR, driven by increasing use of targeted therapies guided by molecular and genetic biomarkers. The report also states that oncology remains the leading precision therapeutics segment in India, with tumor genomics guiding therapy selection, and that biomarker-driven eligibility is becoming standard as therapy labels specify genetic or molecular criteria. This reinforces a cycle where testing capacity and clinical adoption rise together.
Global context helps frame what Indian stakeholders are building toward, without implying the same scale locally. Vantage Market Research estimates the global Precision Oncology and Targeted Cancer Therapeutics Market at USD 122.60 billion in 2025, projected to reach USD 359.60 billion by 2035, growing at a CAGR of 11.47% from 2026 to 2035, and notes North America accounted for approximately 39.07% of global revenue in 2025. Other global research estimates the global precision oncology market at USD 132.87 billion in 2025, projected to reach USD 341.51 billion by 2035 at about a 9.9% CAGR, with Asia-Pacific expected to witness the fastest growth as countries including India expand molecular diagnostics capacity and clinical adoption of biomarker-guided therapies.
What is changing in Precision Oncology India as biomarker-guided care grows?
How fast is India’s cancer biomarkers market projected to grow?
Which biomarker and technology areas stand out in precision oncology market segmentation?
What does the India precision therapeutics outlook suggest for oncology?
